Oslo, 28 July 2016 – PCI Biotech (PCIB) a cancer focused Norwegian biopharmaceutical company, reported today that the first-in-man Phase I study with PCI Biotech’s proprietary drug fimaporfin (Amphinex(TM)) performed at University College Hospital in London in patients with various advanced solid tumours has been published in Lancet Oncology, the premier publication worldwide for original clinical trials research in oncology. The article has the title “Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalization of bleomycin in patients with solid malignancies: A first-in-man phase I dose escalation clinical trial”.
Principal Investigator, Dr. Colin Hopper commented: “The promising tumour responses seen in this heavily pre-treated, difficult to treat patient population with different advanced solid tumours clearly signifies the broad potential of the PCI treatment. The acceptance of this study for publication in this prestigious journal shows the quality of this work, and is an indication of the need for new treatment approaches and the interest in the PCI-application.”
